Clin Cancer Res: Efficacy of Pyrotinib in the treatment of HER2+ breast cancer patients with brain metastases: a real-world multicenter study

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients account for approximately 15-20%, and the prognosis is poor
.

Phase II clinical studies have proved that Pyrotinib combined with capecitabine has a higher objective response rate (ORR) than lapatinib combined with capecitabine, and improves progression-free survival

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients account for approximately 15-20%, and the prognosis is poor

This study is a real-world study evaluating the OS, PFS, tumor mutation burden (TMB), clinical benefit rate (CBR) and objective response of Pyrotinib in the treatment of HER2+ breast cancer patients with brain metastases (BM) Rate (ORR)
.

A total of 168 patients were included in the study.

This study is a real-world study evaluating the OS, PFS, tumor mutation burden (TMB), clinical benefit rate (CBR) and objective response of Pyrotinib in the treatment of HER2+ breast cancer patients with brain metastases (BM) Rate (ORR)

For the overall population, the median follow-up time was 18.

The general population, PFS and OS with or without brain metastases

The general population, PFS and OS with or without brain metastases

Among BM patients, the PFS of the S/R group and the NS/NR group were 9.
97 and 7.
73 months, respectively (p=0.
19).
Furthermore, the S/R group significantly improved OS compared with the NS/NR group, which were 20.
67 and 12.
43 months, respectively Month (p=0.
021)
.

Among BM patients, the PFS of the S/R group and the NS/NR group were 9.
97 and 7.
73 months, respectively (p=0.
19).
Furthermore, the S/R group significantly improved OS compared with the NS/NR group, which were 20.
67 and 12.
43 months, respectively Month (p=0.
021)
.

Among BM patients, the PFS of the S/R group and the NS/NR group were 9.

            Effect of local treatment on PFS and OS in patients with BM

  Effect of local treatment on PFS and OS in patients with BM

The study evaluated the relationship between tumor mutational burden (TMB) and clinical benefit, and divided patients into high TMB and low TMB groups
.

The study found that the PFS of patients with low TMB and high TMB was significantly prolonged, which was 13.

The study evaluated the relationship between tumor mutational burden (TMB) and clinical benefit, and divided patients into high TMB and low TMB groups

           Relationship between TMB and clinical benefit

Relationship between TMB and clinical benefit

In patients with brain metastases, it was also observed that high TMB was negatively correlated with PFS (P = 0.
075) and OS (P = 0.
032)
.

Therefore, high TMB may be a prognostic indicator of pyrrotinib treatment

In patients with brain metastases, it was also observed that high TMB was negatively correlated with PFS (P = 0.

In summary, Pyrotinib is an optional strategy for HER2+ breast cancer patients with brain metastases; its combined surgery or radiotherapy can improve the patient’s OS

Original source:

Munawar Anwar, Qitong Chen, Dengjie Ouyang, et al.
Pyrotinib treatment in patients with HER2-positive metastatic breast cancer and brain metastasis: exploratory final analysis of real-world, multicenter data.
Clin Cancer Res, June 10, 2021.
DOI: 10.
1158 /1078-0432.
CCR-21-0474.

Munawar Anwar, Qitong Chen, Dengjie Ouyang, et al.
Pyrotinib treatment in patients with HER2-positive metastatic breast cancer and brain metastasis: exploratory final analysis of real-world, multicenter data.
Clin Cancer Res, June 10, 2021.
DOI: 10.
1158 /1078-0432.
CCR-21-0474.
Leave a message here